Manipulation of the tumor suppressor p53 for potentiating cancer therapy

Seminars in Cancer Biology

Volumn 14, Issue 4, 2004, Pages 244-252

  Haupt, Susan ^a   Haupt, Ygal ^b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HEBREW UNIVERSITY   (Israel)

Author keywords

DNA damage; Mdm2; P53; Small molecules; Therapy

Indexed keywords

17 ALLYLAMINOGELDANAMYCIN; 4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE; ADAPTOR PROTEIN; ANSAMYCIN DERIVATIVE; ANTINEOPLASTIC AGENT; BORTEZOMIB; CARBOPLATIN; CDB3 PEPTIDE; CHALCONE DERIVATIVE; DOXORUBICIN; DRUG CARRIER; ELLIPTICINE; GELDANAMYCIN; IMIDAZOLE DERIVATIVE; MUTANT PROTEIN; NUTLIN 1; NUTLIN 3; ONYX 015; P53 REACTIVATION AND INDUCTION OF MASSIVE APOPTOSIS 1 PROTEIN; PACLITAXEL; PEPTIDE; PIFITHRIN; PROTEASOME INHIBITOR; PROTEIN P53; TETRACYCLINE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

BLADDER CANCER; BREAST CANCER; CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; EXPRESSION VECTOR; GENE THERAPY; HEAD CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; INFECTION; LUNG CANCER; NECK CANCER; NONHUMAN; OVARY CANCER; PROSTATE CANCER; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; SOLID TUMOR; STRESS;

EID: 3042609978     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2004.04.003     Document Type: Article

References (80)

1. Abarzua P., LoSardo J.E., Gubler M.L., Spathis R., Lu Y.A., Neri A., et al. Restoration of the transcription activation function to mutant p53 in human cancer cells. Oncogene. 13(11):1996;2477-2482
2. Adams J. Proteasome inhibition in cancer: development of PS-341. Semin. Oncol. 28(6):2001;613-619
3. Banerjee R., Basu G., Chene P., Roy S. Aib-based peptide backbone as scaffolds for helical peptide mimics. J. Pept. Res. 60(2):2002;88-94
4. Bergamaschi D., Gasco M., Hiller L., Sullivan A., Syed N., Trigiante G., et al. p53 Polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell. 3(4):2003;387-402
5. Bergamaschi D., Samuels Y., Jin B., Duraisingham S., Crook T., Lu X. ASPP1 and ASPP2: common activators of p53 family members. Mol. Cell Biol. 24(3):2004;1341-1350
6. Bertheau P., Plassa F., Espie M., Turpin E., de Roquancourt A., Marty M., et al. Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet. 360(9336):2002;852-854
7. Blagosklonny M.V., Toretsky J., Bohen S., Neckers L. Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90. Proc. Natl. Acad. Sci. U.S.A. 93(16):1996;8379-8383
8. Blagosklonny M.V., Toretsky J., Neckers L. Geldanamycin selectively destabilizes and conformationally alters mutated p53. Oncogene. 11(5):1995;933-939
9. Blandino G., Levine A.J., Oren M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene. 18(2):1999;477-485
10. Bossi G., Mazzaro G., Porrello A., Crescenzi M., Soddu S., Sacchi A. Wild-type p53 gene transfer is not detrimental to normal cells in vivo: implications for tumor gene therapy. Oncogene. 23(2):2004;418-425
11. Bottger A., Bottger V., Sparks A., Liu W.L., Howard S.F., Lane D.P. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr. Biol. 7(11):1997;860-869
12. Bottger V., Bottger A., Howard S.F., Picksley S.M., Chene P., Garcia-Echeverria C., et al. Identification of novel Mdm2 binding peptides by phage display. Oncogene. 13(10):1996;2141-2147
13. Bullock A.N., Fersht A.R. Rescuing the function of mutant p53. Nat. Rev. Cancer. 1(1):2001;68-76
14. Bykov V.J., Issaeva N., Selivanova G., Wiman K.G. Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. Carcinogenesis. 23(12):2002;2011-2018
15. Bykov V.J., Issaeva N., Shilov A., Hultcrantz M., Pugacheva E., Chumakov P., et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med. 8(3):2002;282-288
16. Bykov V.J., Selivanova G., Wiman K.G. Small molecules that reactivate mutant p53. Eur. J. Cancer. 39(13):2003;1828-1834
17. Chene P. Inhibiting the p53-Mdm2 interaction: an important target for cancer therapy. Nat. Rev. Cancer. 3(2):2003;102-109
18. Courtois S., de Fromentel C.C., Hainaut P. p53 protein variants: structural and functional similarities with p63 and p73 isoforms. Oncogene. 23(3):2004;631-638
19. El-Deiry W.S. The role of p53 in chemosensitivity and radiosensitivity. Oncogene. 22(47):2003;7486-7495
20. el-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., et al. WAF1 a potential mediator of p53 tumor suppression. Cell. 75(4):1993;817-825
21. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 61(5):1990;759-767
22. Fei P., El-Deiry W.S. P53 and radiation responses. Oncogene. 22(37):2003;5774-5783
23. Foster B.A., Coffey H.A., Morin M.J., Rastinejad F. Pharmacological rescue of mutant p53 conformation and function. Science. 286(5449):1999;2507- 2510
24. Friedler A., Hansson L.O., Veprintsev D.B., Freund S.M., Rippin T.M., Nikolova P.V., et al. A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants. Proc. Natl. Acad. Sci. U.S.A. 99(2):2002;937-942
25. Friedler A., Veprintsev D.B., Hansson L.O., Fersht A.R. Kinetic instability of p53 core domain mutants: implications for rescue by small molecules. J. Biol. Chem. 278(26):2003;24108-24112
26. Fujiwara T., Cai D.W., Georges R.N., Mukhopadhyay T., Grimm E.A., Roth J.A. Therapeutic effect of a retroviral wt p53 expression vector in an orthotopic lung cancer model. J. Natl. Cancer Inst. 86(19):1994;1458-1462
27. Garcia-Echeverria C., Chene P., Blommers M.J., Furet P. Discovery of potent antagonists of the interaction between human double min 2 and tumor suppressor p53. J. Med. Chem. 43(17):2000;3205-3208
28. Gudkov A.V. Converting p53 from a killer into a healer. Nat. Med. 8(11):2002;1196-1198
29. Gudkov A.V., Komarova E.A. The role of p53 in determining sensitivity to radiotherapy. Nat. Rev. Cancer. 3(2):2003;117-129
30. Hann B., Balmain A. Replication of an E1B 55-kilodalton protein-deficient adenovirus (ONYX-015) is restored by gain-of-function rather than loss-of-function p53 mutants. J. Virol. 77(21):2003;11588-11595
31. Haupt S., Berger M., Goldberg Z., Haupt Y. Apoptosis-the p53 network. J. Cell Sci. 116(Pt 20):2003;4077-4085
32. Haupt Y., Maya R., Kazaz A., Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 387(6630):1997;296-299
33. Heise C., Sampson-Johannes A., Williams A., McCormick F., Von Hoff D.D., Kirn D.H. ONYX-015, an E1B gene-attenuated adenovirus causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med. 3(6):1997;639-645
34. Honda R., Tanaka H., Yasuda H. Oncoprotein Mdm2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420(1):1997;25-27
35. Hupp T.R., Lane D.P. Allosteric activation of latent p53 tetramers. Curr. Biol. 4(10):1994;865-875
36. Irwin M.S., Kondo K., Marin M.C., Cheng L.S., Hahn W.C., Kaelin W.G. Jr. Chemosensitivity linked to p73 function. Cancer Cell. 3(4):2003;403-410
37. Issaeva N., Friedler A., Bozko P., Wiman K.G., Fersht A.R., Selivanova G. Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide. Proc. Natl. Acad. Sci. U.S.A. 100(23):2003;13303-13307
38. Iwakuma T., Lozano G. Mdm2, an introduction. Mol. Cancer Res. 1(14):2003;993-1000
39. Jimenez G.S., Nister M., Stommel J.M., Beeche M., Barcarse E.A., Zhang X.Q., et al. A transactivation-deficient mouse model provides insights into Trp53 regulation and function. Nat. Genet. 26(1):2000;37-43
40. Kemp C.J., Sun S., Gurley K.E. P53 induction and apoptosis in response to radio-and chemotherapy in vivo is tumor-type-dependent. Cancer Res. 61(1):2001;327-332
41. Kim A.L., Raffo A.J., Brandt-Rauf P.W., Pincus M.R., Monaco R., Abarzua P., et al. Conformational and molecular basis for induction of apoptosis by a p53 C-terminal peptide in human cancer cells. J. Biol. Chem. 274(49):1999;34924-34931
42. Komarov P.G., Komarova E.A., Kondratov R.V., Christov-Tselkov K., Coon J.S., Chernov M.V., et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science. 285(5434):1999;1733-1737
43. Komarova E.A., Neznanov N., Komarov P.G., Chernov M.V., Wang K., Gudkov A.V. p53 Inhibitor pifithrin alpha can suppress heat shock and glucocorticoid signaling pathways. J. Biol. Chem. 278(18):2003;15465-15468
44. Kubbutat M.H.G., Jones S.N., Vousden K.H. Regulation of p53 stability by Mdm2. Nature. 387(6630):1997;299-303
45. Kussie P.H., Gorina S., Marechal V., Elenbaas B., Moreau J., Levine A.J., et al. Structure of the Mdm2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science. 274(5289):1996;948-953
46. Lane D.P. Cancer p53, guardian of the genome. Nature. 358(6381):1992;15-16
47. Lane D.P., Hupp T.R. Drug discovery and p53. Drug Discov. Today. 8(8):2003;347-355
48. Lavarino C., Pilotti S., Oggionni M., Gatti L., Perego P., Bresciani G., et al. p53 Gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. J. Clin. Oncol. 18(23):2000;3936-3945
49. Lebedeva I.V., Su Z.Z., Sarkar D., Fisher P.B. Restoring apoptosis as a strategy for cancer gene therapy: focus on p53 and mda-7. Semin. Cancer Biol. 13(2):2003;169-178
50. Lopes U.G., Erhardt P., Yao R., Cooper G.M. p53-dependent induction of apoptosis by proteasome inhibitors. J. Biol. Chem. 272(20):1997;12893-12896
51. Lowe S.W., Ruley H.E., Jacks T., Housman D.E. p53-Dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74(6):1993;957-967
52. Luu Y., Bush J., Cheung K.J. Jr., Li G. The p53 stabilizing compound CP-31398 induces apoptosis by activating the intrinsic bax/mitochondrial/ caspase-9 pathway. Exp. Cell Res. 276(2):2002;214-222
53. Maloney A., Workman P. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin. Biol. Ther. 2(1):2002;3-24
54. Momand J., Jung D., Wilczynski S., Niland J. The Mdm2 gene amplification database. Nucleic Acids Res. 26(15):1998;3453-3459
55. Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol. Med. 8(4 Suppl):2002;S55-S61
56. Nielsen L.L., Dell J., Maxwell E., Armstrong L., Maneval D., Catino J.J. Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts. Cancer Gene Ther. 4(2):1997;129-138
57. Peng Y., Li C., Chen L., Sebti S., Chen J. Rescue of mutant p53 transcription function by ellipticine. Oncogene. 22(29):2003;4478-4487
58. Protopopova M., Selivanova G. Inhibition of p53 activity in vitro and in living cells by a synthetic peptide derived from its core domain. Cell Cycle. 2(6):2003;592-595
59. Ries S.J., Brandts C.H., Chung A.S., Biederer C.H., Hann B.C., Lipner E.M., et al. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nat. Med. 6(10):2000;1128-1133
60. Rippin T.M., Bykov V.J., Freund S.M., Selivanova G., Wiman K.G., Fersht A.R. Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene. 21(14):2002;2119-2129
61. Rogulski K.R., Freytag S.O., Zhang K., Gilbert J.D., Paielli D.L., Kim J.H., et al. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res. 60(5):2000;1193-1196
62. Roth J., Lenz-Bauer C., Contente A., Lohr K., Koch P., Bernard S., et al. Reactivation of mutant p53 by a one-hybrid adaptor protein. Cancer Res. 63(14):2003;3904-3908
63. Selivanova G., Iotsova V., Okan I., Fritsche M., Strom M., Groner B., Grafstrom R.C., Wiman K.G. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat. Med. 3(6):1997;632-638
64. Selivanova G., Ryabchenko L., Jansson E., Iotsova V., Wiman K.G. Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain. Mol. Cell Biol. 19(5):1999;3395-3402
65. Seo Y.R., Kelley M.R., Smith M.L. Selenomethionine regulation of p53 by a ref1-dependent redox mechanism. Proc. Natl. Acad. Sci. U.S.A. 99(22):2002;14548-14553
66. Shi L.M., Myers T.G., Fan Y., O'Connor P.M., Paull K.D., Friend S.H., et al. Mining the National Cancer Institute Anticancer Drug Discovery Database: cluster analysis of ellipticine analogs with p53-inverse and central nervous system-selective patterns of activity. Mol. Pharmacol. 53(2):1998;241-251
67. Shinohara K., Tomioka M., Nakano H., Tone S., Ito H., Kawashima S. Apoptosis induction resulting from proteasome inhibition. Biochem. J. 317(Pt 2):1996;385-388
68. Stoll R., Renner C., Hansen S., Palme S., Klein C., Belling A., et al. Chalcone derivatives antagonize interactions between the human oncoprotein Mdm2 and p53. Biochemistry. 40(2):2001;336-344
69. Takahashi T., Carbone D., Nau M.M., Hida T., Linnoila I., Ueda R., et al. Wild type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. Cancer Res. 52(8):1992;2340-2343
70. Takimoto R., Wang W., Dicker D.T., Rastinejad F., Lyssikatos J., el-Deiry W.S. The mutant p53-conformation modifying drug CP-31398 can induce apoptosis of human cancer cells and can stabilize wt p53 protein. Cancer Biol. Ther. 1(1):2002;47-55
71. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., et al. In vivo activation of the p53 pathway by small-molecule antagonists of Mdm2. Science. 303(5659):2004;844-848
72. Vecil G.G., Lang F.F. Clinical trails of adenoviruses in brain tumors: a review of Ad-p53 and oncolytic adenoviruses. J. Neurooncol. 65(3):2003;237-246
73. Vogelstein B., Kinzler K.W. p53 function and dysfunction. Cell. 70(4):1992;523-526
74. Vogt Sionov R.V., Haupt Y. The cellular response to p53: the decision between life and death. Oncogene. 18(45):1999;6145-6157
75. Wang H., Oliver P., Zhang Z., Agrawal S., Zhang R. Chemosensitization and radiosensitization of human cancer by antisense anti-Mdm2 oligonucleotides: in vitro and in vivo activities and mechanisms. Ann. N. Y. Acad. Sci. 1002:2003;217-235
76. Wang W., Takimoto R., Rastinejad F., El-Deiry W.S. Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or Mdm2 binding. Mol. Cell. Biol. 23(6):2003;2171-2181
77. Williams S.A., McConkey D.J. The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells. Cancer Res. 63(21):2003;7338-7344
78. Zeimet A.G., Marth C. Why did p53 gene therapy fail in ovarian cancer? Lancet Oncol. 4(7):2003;415-422
79. Zhang Z., Wang H., Prasad G., Li M., Yu D., Bonner J.A., et al. Radiosensitization by antisense anti-Mdm2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models. Clin. Cancer Res. 10(4):2004;1263-1273
80. Zhao J., Wang M., Chen J., Luo A., Wang X., Wu M., et al. The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53-HDM2 complex structure. Cancer Lett. 183(1):2002;69-77